Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$1.63M$1.63M+74.3% vs Q3 2016 Net Income-$5.83M-$5.83MN/M vs Q3 2016 EPS Diluted-$0.27-$0.27N/M vs Q3 2016 Operating Income-$5,889,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,726,000N/M Margins · derivedOperating margin-361.1%−167.0 pt vs Q3 2016
Net margin-357.7%−161.2 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end